August 2017

APAC / August 2017 5 NEWS , This agreement in- cludes the devel- opment of niraparib for the treatment of all tumour types in Japan, and all tumour types ex- cluding prostate cancer in South Korea, Taiwan, Russia and Aus- tralia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly become the most frequently pre- scribed PARP inhibitor in the U.S. Under the terms of this agree- ment, TESARO will receive a $100 million upfront payment and is eligible to receive additional milestone payments of up to $240 million related to the achievement of certain regulatory and commer- cial goals. TESARO will also be eligible to receive from Takeda tiered royalties based on a dou- ble-digit percentage of net prod- uct sales. Takeda gains exclusive commer- cial rights for all potential future niraparib indications in Japan, and rights excluding prostate Gianoni was rec- ognised for his p u r p o s e - d r i v e n leadership and the company’s accel- erated performance alongside CEOs from software companies such as Hubspot, Slack, Sales- force, Gainsight, Box, Workday and more. The CEOs on this year’s list were selected based on five primary factors – company growth, work culture, product technology, finan- cial performance and professional experience. Research was con- ducted using a broad set of data including information from report- ed financials, company press re- leases, Glassdoor, LinkedIn and other sources. Since Gianoni took over as CEO of the social good software lead- er in 2014, Blackbaud’s custom- er base has grown by 20 per- cent, stock price has more than doubled adding over $2 billion in shareholder value, organic growth has tripled and market cap has grown by $2.4 billion. The SaaS Report is a compre- hensive source for business news, investment activity and corporate actions related to the software and SaaS sectors. For more information and to view this year’s list of Top 50 SaaS CEOs, visit 50-saas-ceos-of-2017. For more information, visit Blackbaud CEO Michael ‘Mike’ Gianoni Named One of the Top 50 SaaS CEOs Blackbaud, the world’s leading cloud software company powering social good, recently announced that Michael ‘Mike’ Gianoni, Blackbaud’s president and CEO, has been named to the list of Top 50 SaaS CEOs by The SaaS Report. cancer in South Korea, Taiwan, Russia and Australia. Takeda will be responsible for development of niraparib in Japan and the four specified countries, including all associated expenses. Additional terms of this agreement were not disclosed. “The niraparib development pro- gram addresses many of the most prevalent and devastating cancers worldwide. We must continue to make new treatments available to patients and, through research, further our knowledge into the full utility of this mole- cule,” said Christophe Bianchi, President of Takeda Oncology. “We are pleased to be collaborat- ing with TESARO, a company we admire for its high calibre oncolo- gy expertise. This agreement rep- resents another step in our goal of building Takeda’s robust port- folio in solid tumours and, more importantly, our commitment to patients living with cancer who desperately want - and need - new, innovative therapies.” Once-daily niraparib is the first and only PARP inhibitor that has received approval for the main- tenance treatment of women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status. TESARO’s de- velopment plan currently includes clinical trials of niraparib in pa- tients with ovarian, breast, and lung cancer. Janssen Biotech has licensed rights to develop and commercialise niraparib specif- ically for patients with prostate cancer worldwide, except in Ja- pan. “TESARO is devoted to providing transformative therapies for peo- ple bravely facing cancer, and this partnership enables us to contin- ue to globalise our mission,” said Mary Lynne Hedley, Ph.D., Pres- ident and COO of TESARO. “As the largest pharmaceutical com- pany in Japan, Takeda is recog- nised as a leader in oncology, and we are excited to work with the Takeda team to quickly advance niraparib for patients who need new treatment options.” Niraparib is not currently ap- proved for use in Japan, South Korea, Russia, Taiwan or Aus- tralia. For more information, visit